NeoGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 04:50 pm EDT
Share
NeoGenomics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 146.92 million compared to USD 125.07 million a year ago. Net loss was USD 24.33 million compared to USD 35.3 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.28 a year ago. Diluted loss per share from continuing operations was USD 0.19 compared to USD 0.28 a year ago.
For the six months, revenue was USD 284.14 million compared to USD 242.24 million a year ago. Net loss was USD 55.13 million compared to USD 84.71 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.68 a year ago. Diluted loss per share from continuing operations was USD 0.44 compared to USD 0.68 a year ago.
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
NEOGENOMICS, INC. 
